Published in Br J Cancer on January 01, 1997
Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer (2004) 2.41
The impact of chemotherapy-induced nausea and vomiting on health-related quality of life. Support Care Cancer (2006) 1.41
Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer (2003) 1.36
Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes (2003) 1.34
A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer (2007) 1.27
Palonosetron as an anti-emetic and anti-nausea agent in oncology. Ther Clin Risk Manag (2007) 1.19
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer (2005) 1.18
Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer (2004) 1.16
Stability of an extemporaneous oral liquid aprepitant formulation. Support Care Cancer (2008) 1.13
Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol (2011) 1.10
The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life. Support Care Cancer (2012) 1.08
Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support Care Cancer (2008) 1.05
Chemotherapy-induced nausea and vomiting: optimizing prevention and management. Am Health Drug Benefits (2012) 1.05
One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. Support Care Cancer (2008) 1.00
Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations. Support Care Cancer (2008) 0.99
Symptom assessment in children receiving cancer therapy: the parents' perspective. Support Care Cancer (2009) 0.97
A review of patient self-report tools for chemotherapy-induced nausea and vomiting. Support Care Cancer (2008) 0.97
Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. Support Care Cancer (2014) 0.92
Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapy. Support Care Cancer (2011) 0.90
Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. Support Care Cancer (2007) 0.89
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy. Support Care Cancer (2013) 0.88
A systematic review of symptom assessment scales in children with cancer. BMC Cancer (2012) 0.87
Distress before chemotherapy predicts delayed but not acute nausea. Support Care Cancer (2006) 0.87
Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. Support Care Cancer (2015) 0.86
A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy. Support Care Cancer (2011) 0.86
Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol (2013) 0.85
Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats. Br J Pharmacol (2013) 0.83
Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer (2012) 0.83
Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics. Br J Cancer (2003) 0.83
Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide. Support Care Cancer (2008) 0.83
Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. J Gastroenterol (2013) 0.83
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. Support Care Cancer (2016) 0.83
Nanomedicines in the treatment of emesis during chemotherapy: focus on aprepitant. Int J Nanomedicine (2007) 0.82
A double-blind, crossover, randomized dose-comparison trial of granisetron for the prevention of acute and delayed nausea and emesis in children receiving moderately emetogenic carboplatin-based chemotherapy. Support Care Cancer (2007) 0.81
Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers. Support Care Cancer (2015) 0.81
Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy. Cancer Manag Res (2014) 0.81
Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support Care Cancer (2011) 0.81
A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients. Breast Cancer Res (2013) 0.81
Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting. J Adv Pharm Technol Res (2012) 0.80
Using aprepitant as secondary antiemetic prophylaxis for cancer patients with cisplatin-induced emesis. Support Care Cancer (2011) 0.80
Delayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current Management. Front Pharmacol (2017) 0.79
Interference with acute nausea and anticipatory nausea in rats by fatty acid amide hydrolase (FAAH) inhibition through a PPARα and CB1 receptor mechanism, respectively: a double dissociation. Psychopharmacology (Berl) (2015) 0.79
Effect of selective inhibition of monoacylglycerol lipase (MAGL) on acute nausea, anticipatory nausea, and vomiting in rats and Suncus murinus. Psychopharmacology (Berl) (2014) 0.79
Initial development of the Symptom Screening in Pediatrics Tool (SSPedi). Support Care Cancer (2013) 0.79
Safety of ondansetron loading doses in children with cancer. Support Care Cancer (2007) 0.78
Thermoregulatory correlates of nausea in rats and musk shrews. Oncotarget (2014) 0.78
Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin-cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study. Support Care Cancer (2016) 0.78
Anticipatory nausea in animal models: a review of potential novel therapeutic treatments. Exp Brain Res (2014) 0.78
Suppression of eukaryotic initiation factor 4E prevents chemotherapy-induced alopecia. BMC Pharmacol Toxicol (2013) 0.77
Refinement of the symptom screening in pediatrics tool (SSPedi). Br J Cancer (2014) 0.77
Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens. Am Health Drug Benefits (2015) 0.77
Cytotoxic potential of Anisochilus carnosus (L.f.) wall and estimation of luteolin content by HPLC. BMC Complement Altern Med (2014) 0.77
The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: a retrospective study. Support Care Cancer (2011) 0.77
The cost of chemotherapy-induced nausea and vomiting in Italy. Support Care Cancer (2006) 0.77
The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting. Cancer Manag Res (2015) 0.76
X-ray analysis of the effect of the 5-HT3 receptor antagonist granisetron on gastrointestinal motility in rats repeatedly treated with the antitumoral drug cisplatin. Exp Brain Res (2014) 0.76
Differential pharmacology and clinical utility of rolapitant in chemotherapy-induced nausea and vomiting. Cancer Manag Res (2017) 0.75
Identity-based High-performance thin Layer Chromatography Fingerprinting Profile and Tumor Inhibitory Potential of Anisochilus carnosus (L.f.) wall Against Ehrlich Ascites Carcinoma. Pharmacogn Mag (2015) 0.75
Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy. Int J Clin Oncol (2015) 0.75
Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin. Int J Clin Oncol (2015) 0.75
NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs Context (2017) 0.75
Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis. BMC Med (2016) 0.75
Aprepitant and fosaprepitant use in children and adolescents at an academic medical center. J Pediatr Pharmacol Ther (2014) 0.75
Assessment of low-dose cisplatin as a model of nausea and emesis in beagle dogs, potential for repeated administration. Exp Brain Res (2014) 0.75
Patient preferences for side effects associated with cervical cancer treatment. Int J Gynecol Cancer (2014) 0.75
Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant. Ther Clin Risk Manag (2008) 0.75
Characterization of Dronabinol Usage in a Pediatric Oncology Population. J Pediatr Pharmacol Ther (2016) 0.75
Penny wise, dollar foolish approach to antiemetic use may compromise patient care. J Oncol Pract (2009) 0.75
Hair camouflage: A comprehensive review. Int J Womens Dermatol (2016) 0.75
Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms. Support Care Cancer (2016) 0.75
Hair camouflage: A comprehensive review. Int J Womens Dermatol (2017) 0.75
On the receiving end--patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol (1983) 4.35
On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol (1996) 2.03
The impact of nausea and vomiting upon quality of life measures. Br J Cancer Suppl (1992) 1.81
Fertility after chemotherapy for testicular cancer. J Clin Oncol (1983) 1.32
Side effects and emotional distress during cancer chemotherapy. Cancer (1989) 1.29
Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained. J Clin Oncol (1996) 1.21
The impact of cytotoxic chemotherapy--perspectives from patients, specialists and nurses. Eur J Cancer (1992) 1.01
A comparison of two methods of assessing cancer therapy-related symptoms. Cancer Nurs (1994) 0.97
Chemotherapy: thoughts and images of patients with cancer. Oncol Nurs Forum (1993) 0.88
Family problems during cancer chemotherapy. Oncol Nurs Forum (1993) 0.87
Myths and realities of antiemetic treatment. Br J Cancer Suppl (1992) 0.87
Quality of life measurements in anti-emetic trials: a discussion of Professor Selby's paper. Br J Cancer Suppl (1992) 0.87
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet (2001) 6.11
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer (2001) 4.49
A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med (1992) 4.25
Medical and psychosocial effects of early discharge after surgery for breast cancer: randomised trial. BMJ (1998) 3.90
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet (2005) 3.75
Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve (1991) 3.29
Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer (2002) 3.26
RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer (2006) 3.15
The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology (1998) 3.13
Risk factors for the development of polyneuropathy and myopathy in critically ill patients. Crit Care Med (2001) 2.94
Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys (1999) 2.84
Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst (1997) 2.83
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res (2001) 2.64
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol (1998) 2.52
Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol (2001) 2.52
The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev (1992) 2.44
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer (2002) 2.34
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol (1997) 2.29
Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. J Neurol Neurosurg Psychiatry (1998) 2.24
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst (1999) 2.15
Surgical treatment of lung metastases: The European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer (1996) 2.06
Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res (1999) 2.06
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2001) 1.99
A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer (2001) 1.91
Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer (1994) 1.79
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol (2000) 1.77
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer (2003) 1.75
Meta-analysis of randomized, controlled clinical trials of antibiotic prophylaxis in biliary tract surgery. Br J Surg (1990) 1.75
Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group. Neurology (1996) 1.74
Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer (2003) 1.70
RECIST vs. WHO: prospective comparison of response criteria in an EORTC phase II clinical trial investigating ET-743 in advanced soft tissue sarcoma. Eur J Cancer (2005) 1.69
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol (2008) 1.67
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol (1995) 1.61
Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol (1998) 1.61
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer (1996) 1.58
Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol (1996) 1.58
Role of formulation vehicles in taxane pharmacology. Invest New Drugs (2001) 1.58
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer (2008) 1.57
Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res (2000) 1.57
Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol (1994) 1.56
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer (2013) 1.55
Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther (2008) 1.54
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) Clin Cancer Res (1999) 1.54
miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells. Oncogene (2012) 1.54
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours. Br J Cancer (1998) 1.51
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support. J Natl Cancer Inst (1996) 1.49
Ultrasound-guided aspiration biopsy for detection of nonpalpable axillary node metastases in breast cancer patients: new diagnostic method. World J Surg (1997) 1.48
Utility assessment in cancer patients: adjustment of time tradeoff scores for the utility of life years and comparison with standard gamble scores. Med Decis Making (1994) 1.46
[Treatment of pain in cancer with systemically administered opioids]. Ned Tijdschr Geneeskd (2001) 1.46
Peripheral neurotoxicity induced by docetaxel. Neurology (1996) 1.42
Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer (2002) 1.41
Regulation of cytolytic activity in CD3- and CD3+ killer cell clones by monoclonal antibodies (anti-CD16, anti-CD2, anti-CD3) depends on subclass specificity of target cell IgG-FcR. J Immunol (1987) 1.40
Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor response. J Clin Oncol (1993) 1.39
Indices from flow-volume curves in relation to cephalometric, ENT- and sleep-O2 saturation variables in snorers with and without obstructive sleep-apnoea. Eur Respir J (1995) 1.39
Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol (2001) 1.38
Systematic review on the use of systemic anticancer therapy in renal-impaired gynecological cancer patients. Int J Gynecol Cancer (2007) 1.38
[Chemotherapy in metastasized breast carcinoma]. Ned Tijdschr Geneeskd (1998) 1.38
Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer (2001) 1.37
Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology (2000) 1.36
Characterization and use of a digital light projector for vision research. Vision Res (2001) 1.33
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol (1996) 1.33
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer (2003) 1.32
Lessons learned from independent central review. Eur J Cancer (2009) 1.30
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer (2006) 1.30
Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med (1990) 1.29
Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin Pharmacol Ther (2007) 1.28
Fatigue in immune-mediated polyneuropathies. European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology (1999) 1.27
Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel. Eur J Cancer (2010) 1.26
Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2009) 1.25
Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 1.25
Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer (1996) 1.24
Incisional hernia after upper abdominal surgery: a randomised controlled trial of midline versus transverse incision. Hernia (2009) 1.24